Sökning: onr:"swepub:oai:hhs.se:1155790250006056" >
Cost-effectiveness ...
Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)
-
- Jönsson, Bengt (författare)
- Stockholm School of Economics,Handelshögskolan i Stockholm
-
- Johannesson, Magnus (författare)
- Stockholm School of Economics,Handelshögskolan i Stockholm
-
- Olsson, Anders G (författare)
- Linköping University
-
visa fler...
-
- Pedersen, Terje R (författare)
- University of Oslo
-
- Wedel, Hans (författare)
- Nordic School of Public Health
-
- Kjekshus, John (författare)
- University of Oslo
-
visa färre...
-
(creator_code:org_t)
- Oxford University Press, 1996
- 1996
- Engelska.
-
Ingår i: European heart journal. - : Oxford University Press. - 1522-9645 .- 0195-668X. ; 17:7, s. 1001-1007
- Relaterad länk:
-
https://research.hhs... (primary) (Object in context)
-
visa fler...
-
https://academic.oup...
-
https://research.hhs...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- An analysis of the cost-effectiveness of simvastatin was conducted, based on the Scandinavian Simvastatin Survival Study (4S). The total cost of hospitalization in the placebo group was 52.8 million Swedish kronor (SEK) (5.15 million pounds), compared with SEK 36.0 million (3.51 million pounds) in the simvastatin group. This amounts to a 32% reduction, or a saving of SEK 16.8 million (1.6 million pounds) or SEK 7560 (738 pounds) per patient. The net cost per patient for the duration of the study (5.4 years) was SEK 13,540 (1324 pounds). Simvastatin treatment saved an estimated 0.377 undiscounted life years (0.240 life years discounted at 5% per annum). The cost of simvastatin therapy per discounted life-year saved was therefore SEK 56,400 (5502 pounds). Sensitivity analysis, examining the effect of different life expectancies, costs of initiation and monitoring of simvastatin therapy, and discount rates, showed the results to be stable. Conclusion. The cost per life-year saved of simvastatin in the treatment of post-myocardial infarction and angina patients, as determined from 4S data, is well within the range normally considered cost-effective.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas